MLL4 belongs to the mixed-lineage leukemia (MLL) family of histone lysine methyltransferases, enzymes that particularly methylate histone H3 at lysine 4 (H3K4), a modification pivotal for activating gene transcription. Notably, MLL4 is the largest nuclear protein in mammalian cells and serves as a transcriptional cofactor essential for tissue differentiation, development, and context-dependent regulation of cancer-related genes.

The pioneering work led by Robert Roeder’s Laboratory of Biochemistry and Molecular Biology employed an innovative combination of cryo-electron microscopy (cryo-EM), genetics, and a sophisticated in vitro transcription system developed in their lab to resolve the full nine-subunit architecture of MLL4, including five unique components. The high-resolution structural data revealed that MLL4 anchors rigidly to nucleosomes but extends a flexible arm to recognize histone targets for methylation, effectively switching genes on.

Strikingly, the researchers discovered a unique intramolecular fold where MLL4’s N-terminal region folds back onto its C-terminal domain, forming a structural architecture essential not only for histone methylation but also for facilitating p53-dependent transcriptional activation. Genetic knockout experiments demonstrated that deleting MLL4 impairs transcription of p53 target genes, which are vital for genome protection mechanisms such as DNA repair, cell cycle arrest, and apoptosis.

This newfound co-activator role of MLL4 in assisting p53’s function signifies a second, distinct mechanism by which MLL4 influences gene regulation, beyond its canonical methyltransferase activity. The collaboration between MLL4 and p53 underscores a complex regulatory network that balances oncogenic and tumor-suppressive signals depending on cellular context.

The study’s implications are far-reaching, offering a molecular explanation for MLL4’s dualistic behavior in leukemia and solid tumors. Moving forward, the team aims to elucidate how MLL4 interacts with other leukemia-associated transcription factors, potentially unveiling therapeutic targets that exploit its context-dependent functions.

This research not only deepens our understanding of epigenetic regulation but also highlights MLL4 as a critical modulator in cancer biology, making it a compelling focus for future cancer therapies and transcriptomic studies.

Subject of Research: Epigenetic regulation and cancer transcription mechanisms
Article Title: Molecular Mechanisms of the MLL4 Complex in H3K4 Methylation and p53-Dependent Transcription Activation
Web References: https://www.cell.com/molecular-cell/fulltext/S1097-2765(26)00312-6
Image Credits: Lori Chertoff/The Rockefeller University
Keywords: Leukemia, Epigenetics, Transcription, Cancer, MLL4, p53, Histone Methylation

To elucidate the varied roles of HATs within their respective complexes, researchers have embarked on innovative strategies that leverage chemical biology approaches. One such study presents a novel method to selectively dissociate the ATAC (Ada-two-A-containing) HAT complex from chromatin. The groundbreaking aspect of this approach lies in its intention to preserve other protein complexes intact, thereby mitigating any potential confounding effects that could arise from a more generalized inhibition of histone acetylation at large.

This target-specific strategy is driven by the employment of chemical inhibitors that were meticulously designed to focus on a distinct subunit of the ATAC complex, namely YEATS2. By developing inhibitors that bind specifically to this component of the ATAC complex, researchers have circumvented the complications associated with directly inhibiting the shared catalytic HAT enzymes. The innovation is significant: rather than broadly hindering the acetylation process, it allows for dissection of the contributions made specifically by the ATAC complex.

Among the various compounds tested, the inhibitor LS-170 emerged as the most effective. Its ability to precisely reduce chromatin occupancy of the ATAC complex points to a profound understanding of the HAT’s role in transcriptional regulation. Moreover, the application of LS-170 resulted in a measurable decrease in the level of ATAC-mediated histone acetylation. Histone acetylation is a well-established marker of active transcription and gene expression, implying that the disruption of the ATAC complex could lead to a significant downregulation of genes under its control.

The implications extend beyond biochemical curiosity; the research findings suggest that inhibiting the ATAC complex can have real-world impacts on tumor growth. In a series of experiments conducted with a mouse model of lung cancer, the administration of LS-170 showcased a notable suppression of tumor growth. This therapeutic potential highlights the relevance of targeting specific complexes over generic pathways, thus illustrating a more tailored approach in the ongoing fight against cancer.

Furthermore, this study opens the door to exploring the intricate details of HAT complexes, moving towards a nuanced understanding of how various combinations of cofactors can influence gene expression. The chemical inhibition of the ATAC complex not only provides a functional insight into its role in cancer biology but also establishes a precedent for developing complex-specific inhibitors as a viable therapeutic strategy.

The mechanistic underpinnings of chromatin regulation underscore the essential nature of HATs and their complexity. Researchers are increasingly aware that disruption of a single protein within a larger complex can have cascading effects on gene expression and cellular outcomes. By targeting YEATS2 with LS-170, the researchers have demonstrated a successful methodology for dissecting the functional contributions of protein complexes.

Moreover, the study emphasizes an essential consideration within the field of chemical biology— the need for specificity in inhibitor design. Broad-spectrum inhibitors may yield insights but often at the cost of unintentional consequences on other pathways. The targeted approach exemplified by LS-170 offers a promising alternative, suggesting that similar strategies could be applied to other HAT complexes and enzymes involved in chromatin remodeling.

Understanding the interactions and functional dynamics of the ATAC complex can provide significant insights into cellular processes beyond tumorigenesis, particularly in developmental biology and differentiation. The regulation of gene expression through acetylation has far-reaching consequences, influencing tissue development, cellular identity, and response to external stimuli.

Anticipating future applications, this research paves the way for similar strategies that could unravel the complexities of other protein complexes implicated in various diseases. The ability to selectively manipulate these complexes permits a deeper exploration into cellular mechanisms, granting researchers the flexibility to innovate therapeutically in complex disease contexts.

In summary, the ability to chemically inhibit the ATAC HAT complex has far-reaching implications, not only in our understanding of gene expression regulation but also in the fields of drug development and precision medicine. This research exemplifies the confluence of chemistry and biology in elucidating complex regulatory networks and stipulates a path forward in therapeutic innovation that is both specific and effective.

As research continues to unfold, further studies will likely delve into the long-term effects of complex inhibition, exploring potential resistance mechanisms, and evaluating the translational capacity of these findings to human health and disease.

Moreover, the investigation into ATAC complex biology could ignite new interest in the therapeutic landscapes of other chromatin-modifying complexes, thus broadening the horizon for future research. In doing so, medicine may evolve to more accurately target the complexities of molecular interactions that govern health and disease.

Subject of Research: Histone acetyltransferase complexes and their role in gene regulation and cancer biology.

Article Title: Complex-specific inhibitors for interrogating ATAC histone acetyltransferase complex.

Article References:

Liu, S., Liu, J., Wu, Y. et al. Complex-specific inhibitors for interrogating ATAC histone acetyltransferase complex. Nat Chem Biol (2026). https://doi.org/10.1038/s41589-025-02132-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41589-025-02132-7

Keywords: Histone acetyltransferases, ATAC complex, chromatin regulation, cancer therapy, LS-170, YEATS2